Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
about
Non-natural and photo-reactive amino acids as biochemical probes of immune functionDeveloping strategies in the immunotherapy of leukemiasMDS prognostic scoring systems – past, present, and futureGenetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia.Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotAdoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemiasRepeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyReal-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationClinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities.Increased expression of interferon signaling genes in the bone marrow microenvironment of myelodysplastic syndromes.WT1 gene transcript assay for relapse in acute leukemia after transplantation.Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Monitoring of minimal residual disease in leukemia, advantages and pitfalls.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to successThe biological basis for immunotherapy in patients with chronic myelogenous leukemia.Molecular mechanisms involved in the progression of myelodysplastic syndrome.Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Molecular and genetic features of myelodysplastic syndromes.Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes.T-cell depleted allogeneic hematopoietic cell transplants as a platform for adoptive therapy with leukemia selective or virus-specific T-cells.Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection.Bone marrow fibrosis in myelodysplastic syndromes: a prospective evaluation including mutational analysis.Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia.Effective treatment of leukemic cell lines with wt1 siRNA.Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein.Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.Ectopic expression of C/EBPalpha and ID1 is sufficient to restore defective neutrophil development in low-risk myelodysplasiaPreferentially Expressed Antigen of Melanoma (PRAME) and Wilms' Tumor 1 (WT 1) Genes Expression in Childhood Acute Lymphoblastic Leukemia, Prognostic Role and Correlation with Survival.Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
P2860
Q21144124-052F2A4C-032D-4950-A2D3-7163A240D3F8Q26996310-ECA72F60-C05B-4ED0-86A9-1BA097FC2FB6Q28082460-C8435773-85B0-410D-95CB-32044A828C41Q33270804-FD60C252-613F-441C-8997-46284D0BA5A1Q33284886-6AA0DA9F-38F3-439A-8852-D8DAD65C4DCBQ33679140-CC78DCCC-3469-4FE4-85DF-3CE8FFF954CBQ34013786-07FAA34B-39F1-4E6C-9A0C-E8B78ECBDC30Q34180369-69BFEDD9-4A1B-431D-95AC-3010FBB69210Q34279672-88092DA7-DFD6-4996-B2C1-0E1E5BE83CC7Q34374079-F83184EF-F98C-4BA2-BD36-3B97F4ABC388Q34612637-D5BA5EBA-FE50-4848-9A4E-F9F90DE06B28Q34617770-FA0BB6DC-338D-4E57-9388-059B64E18163Q34707452-04A6FB92-6125-46EF-9B8C-3E8D96C2D16CQ34861985-FA29058E-DD14-45F7-87D2-6BBDB66EF91BQ35082495-B23BD604-BE7F-4C33-99DA-05DB75508077Q35214418-2B5A44A2-6791-49CD-9565-E33DF2EF752DQ35821007-20422B40-2CFC-424C-AC91-DCBAEBB6E72FQ35990687-5389DC53-8898-41AE-A3CC-F8C716807124Q36194241-6D55256A-A364-425D-9C3E-E3BE16874D30Q36384606-C2883799-AC2B-409A-AA69-C643E36FACABQ36652555-4ED88D3C-FB69-461D-8E1D-18437052DE3BQ36793112-EB1A66C8-ED13-464C-99D1-B6CA72602416Q37222206-1BC6419A-A70D-4353-B35C-6D01D667841EQ37428671-BA1A7F2A-ACD9-4FB4-A911-7BA1B627A6F7Q37707390-2E379033-D687-4EB3-A43B-29055EB1DA31Q37872296-129EB5C6-4F9F-4AE2-9DB2-E422B5870FFBQ37972713-5B1D4C50-25DF-44D6-82C0-38443206F9F2Q38122703-96972D13-5E6E-4FA4-8E4A-9849EB364A39Q38514497-BED88C49-DA1B-42AB-B411-CB9F35FC6B95Q38947873-9B59135A-E28C-4413-AA71-D00B1210E2A5Q39264807-944C50C3-664A-4054-8DB7-DDF6B20706FCQ39811365-27A808D8-650D-4EEE-AE5F-EAE4B02641E3Q39992358-6C036B91-D3E2-4AD3-8A96-FD3353B3D761Q40035267-E994CBB4-1141-49D1-B401-F2CFD3A8C13DQ40095623-F2CD8BCB-48CE-46C5-9376-1E3665A72A9AQ40228775-37320E8C-2016-4C97-8304-52CC677B9BCCQ40808695-872A0BE0-671F-421D-A96A-30A01769FCBEQ42662362-83976ADE-E3CE-405C-8BB0-7C1DC1611A6FQ42767013-B5A50296-8E4A-4ECF-8B75-BEE0DB0D8695Q44527886-D5CA87BF-8FDF-4BBE-BAED-72A103906A8D
P2860
Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Significant correlation betwee ...... ith myelodysplastic syndromes.
@en
Significant correlation betwee ...... ith myelodysplastic syndromes.
@nl
type
label
Significant correlation betwee ...... ith myelodysplastic syndromes.
@en
Significant correlation betwee ...... ith myelodysplastic syndromes.
@nl
prefLabel
Significant correlation betwee ...... ith myelodysplastic syndromes.
@en
Significant correlation betwee ...... ith myelodysplastic syndromes.
@nl
P2093
P356
P1476
Significant correlation betwee ...... ith myelodysplastic syndromes.
@en
P2093
Alessandro Levis
Andrea Gallamini
Carlo Marinone
Daniela Cilloni
Dario Ferrero
Enrico Gottardi
Francesca Messa
Giuseppe Saglio
Marilena Bertini
Mauro Girotto
P304
P356
10.1200/JCO.2003.10.503
P407
P577
2003-05-01T00:00:00Z